Avidity Biosciences, Inc.RNAEarnings & Financial Report

Nasdaq · pharmaceutical industry

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

Revenue

$12.5M

Gross Profit

N/A

Operating Profit

$-188.8M

Net Profit

$-174.4M

Gross Margin

N/A

Operating Margin

-1513.5%

Net Margin

-1398.3%

YoY Growth

434.0%

EPS

$-1.27

Financial Flow

Avidity Biosciences, Inc. Q3 2025 Financial Summary

Avidity Biosciences, Inc. reported revenue of $12.5M for Q3 2025, with a net profit of $-174.4M (-1398.3% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue	$12.5M
Net Profit	$-174.4M
Gross Margin	N/A
Operating Margin	-1513.5%
Report Period	Q3 2025

Avidity Biosciences, Inc. Annual Revenue by Year

Avidity Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $10.9M).

Year	Annual Revenue
2024	$10.9M
2023	$9.6M
2022	$9.2M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$2.2M	$3.5M	$2.0M	$2.3M	$3.0M	$1.6M	$3.8M	$12.5M
YoY Growth	-20.8%	58.7%	-11.7%	-17.1%	35.6%	-55.6%	88.1%	434.0%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$628.6M	$951.5M	$1.35B	$1.64B	$1.56B	$1.46B	$1.37B	$2.13B
Liabilities	$127.8M	$120.6M	$126.4M	$137.4M	$138.9M	$130.4M	$176.3M	$247.9M
Equity	$500.8M	$830.9M	$1.22B	$1.50B	$1.42B	$1.33B	$1.19B	$1.89B